Last updated on February 2011

Study of Anxiety in African American Men With Prostate Cancer


Brief description of study

RATIONALE: Questionnaires that measure anxiety, depression, and quality of life may improve the ability to plan treatment for patients with prostate cancer. PURPOSE: This clinical trial is studying anxiety, depression, and quality of life in African-American patients with prostate cancer.

Detailed Study Description

OBJECTIVES: Primary - To establish the psychometric properties of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) in African American men with prostate cancer. - To establish the reliability of the MAX-PC in African American men with prostate cancer. - To establish the validity of the MAX-PC in African American men with prostate cancer. - To confirm the factor structure of the MAX-PC in this sample. - To test the sensitivity to change of the MAX-PC in this sample. Secondary - To explore the prevalence of distress, anxiety, and depression in African American men with prostate cancer. OUTLINE: This is a multicenter study. All patients complete a 5-minute Memorial Anxiety Scale for Prostate Cancer (MAX-PC) questionnaire measuring general prostate cancer anxiety, PSA anxiety, and fear of recurrence either in person or by phone. They will complete six other questionnaires, each requiring 5 minutes to complete, and focusing on anxiety, depression, and quality of life measures. These include the demographic questionnaire; the Distress Thermometer visual analogue scale; the Hospital Anxiety and Depression Scale (HADS); the Functional Assessment of Cancer Therapy Scale-Prostate (FACT-P); the Center for Epidemiologic Studies Depression Scale (CES-D) assessing the frequency of depressive symptoms the patient experienced in the past week; and the Karnofsky Patient Performance Rating Scale (KPRS). Within 1 week after receiving their PSA test results, some patients will undergo an additional telephone interview conducted by a research study assistant to complete the MAX-PC, the HADS, and the Distress Thermometer questionnaires. PROJECTED ACCRUAL: A total of 150 patients (75 patients with early stage disease and 75 patients with late stage disease) will be accrued for this study.

Clinical Study Identifier: NCT00602654

Find a site near you

Start Over

Memorial Sloan-Kettering Cancer Center

New York, NY United States
6.63miles
  Connect »

SUNY Downstate Medical Center

Brooklyn, NY United States
6.79miles
  Connect »